Jeff Yass’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$390K Buy
28,597
+10,905
+62% +$144K ﹤0.01% 10355
2026
Q2
$167K Sell
17,692
-3,525
-17% -$33.7K ﹤0.01% 12115
2026
Q1
$194K Buy
+21,217
New +$178K ﹤0.01% 11742
2025
Q3
– Sell
-62,211
Closed -$432K – 12472
2025
Q2
$412K Buy
62,211
+6,952
+13% +$49.3K ﹤0.01% 9612
2025
Q1
$506K Buy
55,259
+27,967
+102% +$279K ﹤0.01% 8883
2024
Q4
$287K Buy
+27,292
New +$323K ﹤0.01% 9935
2024
Q3
– Sell
-109,301
Closed -$945K – 12035
2024
Q2
$628K Sell
109,301
-180,342
-62% -$989K ﹤0.01% 7717
2024
Q1
$1.51M Buy
289,643
+33,917
+13% +$166K ﹤0.01% 6000
2023
Q4
$1.35M Buy
255,726
+74,064
+41% +$293K ﹤0.01% 6247
2023
Q3
$599K Buy
181,662
+82,625
+83% +$290K ﹤0.01% 7805
2023
Q2
$286K Buy
99,037
+57,720
+140% +$111K ﹤0.01% 9534
2023
Q1
$44.2K Buy
+41,317
New +$79K ﹤0.01% 11744
2022
Q3
– Sell
-10,373
Closed -$81.2K – 13206
2022
Q2
$71K Buy
+10,373
New +$106K ﹤0.01% 11750
2021
Q2
– Sell
-14,638
Closed -$224K – 12579
2021
Q1
$224K Buy
+14,638
New +$209K ﹤0.01% 11194

Other funds holding BVS

Jeff Yass's BVS Position: Q3 2026 in Review

Jeff Yass increased its Bioventus (BVS) stake by 62% in Q3 2026, buying an estimated $144K and bringing the position to 28,597 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #10355.

Jeff Yass first reported a position in BVS in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.51M in Q1 2024. 169 funds tracked by Wall St. Rank hold BVS as of Q3 2026.

  • Jeff Yass held 28,597 shares of Bioventus worth $390K as of Q3 2026.
  • Jeff Yass bought 10,905 Bioventus shares in Q3 2026, an estimated $144K.
  • Bioventus made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #10355 holding.
  • Jeff Yass first reported a position in Bioventus in Q1 2021 and has held it in 14 quarters since.
  • Jeff Yass's Bioventus position peaked at $1.51M in Q1 2024.
  • 169 funds tracked by Wall St. Rank held Bioventus as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.